We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Drug Products » Commissioner Gottlieb’s FDA: His First Year and a Look Ahead - Webinar Recording/Transcript

Other Options

Audio Recording/Transcript - Aug. 16, 2018

$287.00

Audio Recording/Transcript - Aug. 16, 2018

$258.00

Audio Recording/Transcript - Aug. 16, 2018

$244.00

Audio Recording/Transcript - Aug. 16, 2018

$230.00

Audio Recording/Transcript - Aug. 16, 2018

$215.00

Commissioner Gottlieb’s FDA: His First Year and a Look Ahead - Webinar Recording/Transcript

$287.00
Drug Products

Product Details

Commissioner Gottlieb’s FDA: His First Year and a Look Ahead

What we know about the Gottlieb FDA: That lots is getting done.

What we need to know: What will he do next?

Who owns the crystal ball: Wayne Pines, long-time FDA spokesman and now a sought-after consultant, fronting a panel of FDA-watchers and gurus (TBA).

What you need to know: Where to sign up.

For 90 minutes, Pines and team will lay out the key initiatives to date plus what to expect down the road. Here’s just a taste of what you’ll discover:

  • Drug pricing and marketing: What the Commissioner is trying to change, and how he’s going about making it happen
  • Drug and device approvals: How the process has changed, how it could change in the future
  • The opioid crisis: Comr. Gottlieb’s strategy to deal with it
  • Enforcement: Gottlieb priorities and how they’ll affect you
  • The Gottlieb agenda: Now – and down the road
  • And MUCH more!

In only his first year, Gottlieb and the FDA have taken actions intended to lower drug prices and alter the economics of healthcare delivery. Every drug and device maker, not to mention clinical trial operators and other FDA-regulated players, need to know what the Commissioner still has in store. Here’s how to find out … from folks who know.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing